Brevan Howard Capital Management’s Orchestra BioMed OBIO Stock Holding History

Brevan Howard Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$156K	Buy	+36,769	New	+$157K	﹤0.01%	1955

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Brevan Howard Capital Management's OBIO Position: Q1 2026 in Review

Brevan Howard Capital Management opened a new position in Orchestra BioMed (OBIO) in Q1 2026: 36,769 shares worth $156K. The stake represents ﹤0.01% of the portfolio and ranks #1955 among its holdings.

65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Brevan Howard Capital Management held 36,769 shares of Orchestra BioMed worth $156K as of Q1 2026.
Orchestra BioMed was a new Brevan Howard Capital Management position in Q1 2026.
Orchestra BioMed made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1955 holding.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.